71.51
0.53%
0.38
After Hours:
50.00
-21.51
-30.08%
Exact Sciences Corp stock is traded at $71.51, with a volume of 3.69M.
It is up +0.53% in the last 24 hours and up +4.61% over the past month.
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.
See More
Previous Close:
$71.13
Open:
$70.56
24h Volume:
3.69M
Relative Volume:
1.80
Market Cap:
$13.21B
Revenue:
$2.53B
Net Income/Loss:
$-240.23M
P/E Ratio:
-45.10
EPS:
-1.5857
Net Cash Flow:
$-20.46M
1W Performance:
+2.69%
1M Performance:
+4.61%
6M Performance:
+15.21%
1Y Performance:
+6.70%
Exact Sciences Corp Stock (EXAS) Company Profile
Name
Exact Sciences Corp
Sector
Industry
Phone
608-284-5700
Address
5505 ENDEAVOR LANE, MADISON, WI
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-28-24 | Initiated | Wells Fargo | Overweight |
Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
Jun-03-24 | Resumed | Jefferies | Buy |
Jan-02-24 | Upgrade | The Benchmark Company | Hold → Buy |
Dec-14-23 | Initiated | Guggenheim | Buy |
Dec-13-23 | Initiated | Wolfe Research | Outperform |
Oct-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
Sep-28-23 | Initiated | Bernstein | Outperform |
Aug-02-23 | Downgrade | The Benchmark Company | Buy → Hold |
May-10-23 | Upgrade | Craig Hallum | Hold → Buy |
May-05-23 | Initiated | UBS | Neutral |
Mar-09-23 | Upgrade | Citigroup | Neutral → Buy |
Feb-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
Oct-19-22 | Downgrade | Craig Hallum | Buy → Hold |
Aug-25-22 | Initiated | Credit Suisse | Outperform |
Jun-03-22 | Initiated | Piper Sandler | Neutral |
Nov-03-21 | Downgrade | Raymond James | Strong Buy → Outperform |
Jul-29-21 | Reiterated | BTIG Research | Buy |
Jul-29-21 | Reiterated | Canaccord Genuity | Buy |
Jul-29-21 | Reiterated | Oppenheimer | Outperform |
Jul-29-21 | Reiterated | Stifel | Buy |
Jun-15-21 | Initiated | Raymond James | Strong Buy |
Jun-03-21 | Initiated | Goldman | Buy |
May-25-21 | Initiated | Wells Fargo | Equal Weight |
Jan-28-21 | Initiated | Truist | Buy |
Oct-29-20 | Downgrade | UBS | Buy → Neutral |
Oct-28-20 | Downgrade | Citigroup | Buy → Neutral |
Oct-08-20 | Resumed | BTIG Research | Buy |
Apr-02-20 | Initiated | Evercore ISI | Outperform |
Jan-10-20 | Resumed | BTIG Research | Buy |
Jan-07-20 | Initiated | Citigroup | Buy |
Dec-13-19 | Initiated | Dougherty & Company | Buy |
Nov-15-19 | Initiated | Stifel | Buy |
Oct-17-19 | Reiterated | BofA/Merrill | Buy |
Oct-01-19 | Resumed | Craig Hallum | Buy |
Sep-26-19 | Initiated | Oppenheimer | Outperform |
Feb-26-19 | Upgrade | Goldman | Neutral → Buy |
Oct-09-18 | Initiated | UBS | Buy |
Sep-05-18 | Resumed | The Benchmark Company | Hold |
Aug-13-18 | Reiterated | Canaccord Genuity | Buy |
Apr-03-18 | Upgrade | BTIG Research | Neutral → Buy |
Jan-29-18 | Initiated | Goldman | Neutral |
Jan-08-18 | Reiterated | The Benchmark Company | Buy |
Nov-13-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
Nov-01-17 | Downgrade | BTIG Research | Buy → Neutral |
View All
Exact Sciences Corp Stock (EXAS) Latest News
Exact Sciences: Q3 Earnings Snapshot - San Antonio Express-News
After-hours movers: Super Micro Computer, Exact Sciences, Trump Media & Technology - Investing.com
Exact Sciences Stock Plummets After Worse-Than-Expected Q3 Results, FY24 Guidance Below Estimates - Benzinga
Exact Sciences Corp Q3 2024 Earnings: Revenue at $709M, EPS at -$0.21, Misses Estimates - GuruFocus.com
Exact Sciences shares plummet on weak results, lowered guidance By Investing.com - Investing.com UK
Exact Sciences Announces Third-Quarter 2024 Results - StockTitan
New York State Common Retirement Fund Has $20.19 Million Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
3 Large-Cap Stocks to Buy Ahead of Likely Earnings Beat Tuesday - Yahoo Finance
Exact Sciences Corp (EXAS) Stock Price Up 2.99% on Nov 4 - GuruFocus.com
Exact Sciences to Participate in November Investor Conference - Marketscreener.com
Canaccord Genuity sees upside potential for Exact Sciences shares, lifts PT - Investing.com
Exact Sciences (EXAS) Moves to Strong Buy: Rationale Behind the Upgrade - Yahoo Finance
Exact Sciences (EXAS) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement - Business Wire
8,360 Shares in Exact Sciences Co. (NASDAQ:EXAS) Purchased by Sequoia Financial Advisors LLC - MarketBeat
Exact Sciences Co. (NASDAQ:EXAS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Will Screening Sales Drive Exact Sciences' Q3 Earnings? - Yahoo Finance
Exact Sciences Corp (EXAS) Shares Gap Down to $69.69 on Oct 21 - GuruFocus.com
Can This Beaten-Down Cathie Wood Stock Bounce Back? - MSN
Friedenthal Financial Purchases New Stake in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Cor (EXAS-Q) QuotePress Release - The Globe and Mail
Exact Sciences Corporation (EXAS) Bounced Back in Q3 - Yahoo Finance
EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening - Yahoo Finance
Artemis Investment Management LLP Invests $7.27 Million in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences EVP sells shares worth over $65k - Investing.com India
Exact Sciences EVP sells shares worth over $65k By Investing.com - Investing.com Australia
Exact Sciences Co. (NASDAQ:EXAS) EVP Brian Baranick Sells 929 Shares - MarketBeat
Exact Sciences Corp (EXAS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Exact Sciences Corp (EXAS) Q2 2024 Earnings Call Highlights: Str - GuruFocus.com
Handelsbanken Fonder AB Acquires 9,400 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Schedules Third Quarter 2024 Earnings Call - BioSpace
Exact Sciences stock advances on Cologuard Plus approval, BTIG bullish By Investing.com - Investing.com Australia
FMR LLC Bolsters Stake in Exact Sciences Corp - GuruFocus.com
Exact Sciences stock advances on Cologuard Plus approval, BTIG bullish - Investing.com India
FDA greenlights Exact Science’s newest home colorectal cancer test - Medical Device Network
Exact Sciences wins FDA approval for Cologuard Plus colorectal cancer test - Yahoo Finance
Exact Sciences Corporation (EXAS): A Buzzing AI Health Stock to Add to Your Portfolio - Insider Monkey
10 Buzzing AI Health Stocks - Insider Monkey
FDA approves Exact Sciences' advanced CRC screening test By Investing.com - Investing.com South Africa
FDA approves Exact Sciences' advanced CRC screening test - Investing.com India
Exact Sciences shares hold as FDA approves new Cologuard test - Investing.com
FDA greenlights Exact Sciences’ Cologuard Plus - BioWorld Online
Exact Sciences shares hold as FDA approves new Cologuard test By Investing.com - Investing.com Canada
FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test - Yahoo Finance
Is EXAS Stock a Smart Addition to Your Portfolio Right Now? - Yahoo Finance
Exact Sciences (EXAS) Announces FDA Approval of Cologuard Plus Test - StreetInsider.com
FDA Approves Exact Sciences’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening - The Bakersfield Californian
Curbstone Financial Management Corp Decreases Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Corp Stock (EXAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):